Tacrolimus toxicity due to drug interaction with mibefradil in a patient after liver transplantation

Zeitschrift fur Gastroenterologie

Volumn 37, Issue 10, 1999, Pages 1025-1028

  Ocran, K W ^c   Plauth, Mathias ^b   Mai, I ^a   Lochs, H ^c  

^a HUMBOLDT UNIVERSITY   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c NONE

Author keywords

Cyclosporine; Cytochrome P 450; Drug interactions; Liver transplantation; Mibefradil; Tacrolimus

Indexed keywords

CALCIUM CHANNEL BLOCKING AGENT; CERATE; CREATININE; CYTOCHROME P450; MIBEFRADIL; POTASSIUM; TACROLIMUS; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CASE REPORT; COMPETITIVE INHIBITION; DRUG BLOOD LEVEL; DRUG INTERACTION; DRUG METABOLISM; DRUG TOXICITY; FATIGUE; HUMAN; HYPERTENSION; LIVER TRANSPLANTATION; MALE; MYALGIA; NEPHROTOXICITY; VERTIGO;

ANTIHYPERTENSIVE AGENTS; CALCIUM CHANNEL BLOCKERS; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIVER TRANSPLANTATION; MALE; METABOLIC CLEARANCE RATE; MIBEFRADIL; MIDDLE AGED; TACROLIMUS;

EID: 0032841915     PISSN: 00442771     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Guckelberger O, Bechstein WO, Neuhaus R et al. Cardiovascular risk factors in long-term follow-up after orthotopic liver transplantation. Clin Transplant 1997; 11: 60-5
2. Williams R, Neuhaus P, Bismuth H et al. Two-year data from the European multicentre tacrolimus (FK506) liver study. Transpl Int 1996; 9 (suppl. 1): S144-S150
3. 2+ channels by Ro 40-5967. Circ Res 1994; 75: 144-8
4. Arzneimittelkommission der deutschen Ärzteschaft. Rückruf von Cerate (Mibefradil) angeordnet. Dtsch Ärztebl 1998; 95: B1838
5. Wiltshire HR, Sutton BM, Heeps G et al. Metabolism of the calcium antagonist, mibefradil (Posicor, Ro 40-5967). Part III. Comparative pharmacokinetics of mibefradil and its major metabolites in rat, marmoset, cynomolgus monkey and man. Xenobiotica 1997; 27: 557-71
6. Miller DB, Spence JD. Clinical pharmacokinetics of fibric acid derivatives (fibrates). Clin Pharmacokinet 1998; 34: 155-62
7. Ernst ME, Kelly MW. Mibefradil, a pharmacologically distinct calcium antagonist. Pharmacotherapy 1998; 18: 463-85
8. Regazzi MB, Iacona I, Campana C et al. Clinical efficacy and pharmacokinetics of HMG-CoA reductase inhibitors in heart transplant patients treated with cyclosporin A. Transplant Proc 1994; 26: 2644-5
9. Langouet S, Coles B, Morel F et al. Inhibition of CYP1A2 and CYP3A4 by oltipraz results in reduction of aflatoxin Bl metabolism in human hepatocytes in primary culture. Cancer Res 1995; 55: 5574-9
10. Mignat C. Clinically significant drug interactions with new immunosuppressive agents. Drug Saf 1997; 16: 267-78
11. Padhi ID, Long P, Basha M, Anandan JV. Interaction between tacrolimus and erythromycin. Ther Drug Monit 1997; 19: 120-2
12. Osowski CL, Dix SP, Lin LS et al. Evaluation of the drug interaction between intravenous high-dose fluconazole and cyclosporine or tacrolimus in bone marrow transplant patients. Transplantation 1996; 61: 1268-72
13. Christians U, Schmidt G, Bader A et al. Identification of drugs inhibiting the in vitro metabolism of tacrolimus by human liver microsomes. Br J Clin Pharmacol 1996; 41: 187-90